Recursion Pharmaceuticals Inc vs Zillow Group Inc Class C — how do they compare? Recursion Pharmaceuticals Inc trades at $4.33 (market cap $2.14B), while Zillow Group Inc Class C trades at $28.9 (market cap $6.59B). The key difference: Zillow Group Inc Class C is far larger — about 3.1× Recursion Pharmaceuticals Inc's market cap, and Recursion Pharmaceuticals Inc is trading nearer its 52-week high, Zillow Group Inc Class C nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Recursion Pharmaceuticals Inc for 23 Days and Zillow Group Inc Class C for 38 Days on average.
| RXRX | Z | |
|---|---|---|
Market Cap | $2.14B | $6.59B |
Volume | 30,789,535 | 9,134,294 |
Sector | Health | Media |
52-Week High | $6.79 | $78.04 |
52-Week Low | $2.84 | $27.13 |
Typical Hold Time | 23 Days | 38 Days |
Enterprise Value | $1.66B | $6.47B |
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $4.255, down 0.35% on the day, with a bullish technical signal from moving averages. The company reported a net loss of $644.76 million in 2025 on $74.26 million revenue, with a negative net income margin of -961.97%. Recent news highlights strategic AI partnerships, including an extended data license with Tempus AI announced September 21, 2026, and pipeline progress presented at the Morgan Stanley Healthcare Conference.
The outlook remains speculative, driven by AI-powered drug discovery potential and partnership milestones, but significant execution risk persists due to heavy losses and high cash burn. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for long-term platform value against near-term financial challenges.
Zillow Group (Z) trades at $28.84, up 5.72% in the last session, showing strong momentum despite mixed technical signals. The company has demonstrated improving fundamentals with revenue growing from $2.2B in 2024 to $2.6B in 2025, turning a net loss of $112M into a $23M profit. Recent earnings show beats in Q1 and Q2 2026, though Q4 2025 missed expectations. Analyst sentiment is divided with a $60.33 consensus price target representing significant upside potential from current levels.
Zillow presents a compelling growth story with improving profitability and strong analyst targets, but faces headwinds from housing market volatility and rising mortgage rates. The stock's high P/E ratio of 126.83 reflects growth expectations, while technical indicators show conflicting signals with bullish overall momentum but bearish moving averages. The resolution of the FTC lawsuit removes regulatory overhang, but competition with Compass and market sensitivity to interest rates remain key risks.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →Zillow Group is an online real estate company that simplifies buying, selling, renting, and financing properties. It partners with agents, brokers, and landlords, combining technology with quality service. Its brands include Zillow, Trulia, StreetEasy, and Hotpads.
Read more on Z →